Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm hoping that the last SEC document wasn't referring to the last funding with Mr Bigger.
Here's hoping something new is in the works
I'm not buying any more till AF gives me the OK
That will lighten things up on this board ! LOL
Can't place enough LOL on this message
My big gut is starting to hurt ! LOL
Don't Make me Leak ( Until Saturday Maybe)
And the Sweet deal really is,
Someday Soon it won't be IMMINENT ! --- It will be Now !
Bread Crumbs all over the place !
Just like when Netflix went from only sending Disks through the mail to now on every TV. Bread Crumbs
Yes - I'm using NetFlix as an example --- were most likely larger
Its 15 pages so I'm jumping around -- I don't have time to do it right -- Limited to 150 words at a time ugh
But this was interesting -- there might be some interesting info in the paper
6.2 INCOMPATIBILITIESTake no compatibility studies and should not be mixed with other medicinal products.6.3 EXPOSURE TO STABILITYStored in cryoshipper at temperatures of ≤ -110 ° C, the product is available for 11 days. Store product at room temperature for no longer than 30 minutes after thawing.6.4 SPECIAL STORAGE INSTRUCTIONS CFAX-L must be stored in cryoshipper at temperatures of ≤ -110 ° C. After thawing at room temperature (thawing time of up to 10 minutes) and start-up, DCVax-L must be applied immediately, ie after 30 minutes at the latest. The product can not be frozen again after thawing. The product contains dimethyl sulfoxide, which can cause damage to the living cells if the product remains at room temperature for more than 30 minutes.6.5 TYPE AND CONTENTS OF THE CONTAINER DCVax-L is available in plastic cryovials (1 ml) with screw cap.
Northwest Biotherapeutics,
GmbH
DCVax-L 1.25 x 106
living dendritic
Cells / cryovial
suspension for injection
2.15
The application has been qualified by a trained in dealing with DCVax-L qualified
Specialist and is on appropriately specialized facilities
limited to medical care.
DCVax-L is an individual preparation exclusively for autologous use
certainly.
Since leukapheresis is mandatory for the production of DCVax-L,
It must be ensured that the patient has adequate bone marrow function
features. Therefore, the complete blood count should be determined before the first leukapheresis
and have acceptable values. Leukapheresis needs to be done by a doctor
be carried out with product-specific expertise.
During the treatment cycle, patients are careful and regular too
check.
DCVax-L should only be administered after the patient has withdrawn from the surgical
Recovery and additional cell-reducing treatments such as radiation,
Chemotherapy, or a combination of both. These
Treatments may vary depending on the findings or disease stage of the patient
be different.
dosage
Two intradermal injections are recommended for each immunization
(corresponds to a single dose). Each injection contains 1.25 x 106
the one with
Tumor lysate antigen of the patient incubated autologous dendritic cells. The at
each immunization administered total dose is 2.5 x 106
the one with
Tumor lysate antigen of the patient incubated autologous dendritic cells.
type of application
DCVax-L is a series of two intradermal injections (equivalent to one)
Single dose) into the upper arm (change of upper arm at each dose).
The first dose (day 0 of the following schedule) may take about 4 - 6 weeks after
Leukapheresis can be given to the preparation and release of the product
to allow.
The first immunization should not be earlier than 10 days after the termination of one
possible steroid treatment. It is recommended the following doses
8 - 12 days, 18 - 22 days, 2 months, 4 months, 8 months, 12 months, 18 months,
24 months, 30 months and 36 months after the first immunization too
administer.
Immunization with DCVax-L should not be concomitant with administration of
Temozolomide done. It is recommended one day before and 7 days after
Immunization not to administer temozolomide.
The further treatment regimen of DCVax-L is then the treatment scheme
to adapt to temozolomide.
The following immunization scheme is recommended:
Immunization no.
(2 injections each)
Time
1 day 0
2 8 - 12 days after immunization no. 1
3 18 - 22 days after immunization no. 1
4 2 months after immunization No. 1
5 4 months after immunization # 1
6 * 8 months after immunization # 1
7 * 12 months after immunization no. 1
Continuing * Every 6 months
* as long as the product is available and its shelf life has not expired (maximum 36
Months).
Children and adolescents
The safety and efficacy of DCVax-L in children and adolescents is not
demonstrated. Therefore, DCVax-L should not be used in children and adolescents
be applied.
4.3 CONTRAINDICATIONS
DCVax-L may not be used with:
? Hypersensitivity to one or more of those mentioned in section 6.1
other ingredients of DCVax-L.
? Patients suffering from active infections, HIV positive, Hepatitis B / C positive,
or suffering from syphilis.
? Patients with a history of reduced immune competence or
Autoimmune disease suffered and patients with allogeneic organ transplant or
another uncontrolled systemic, malignant disease that is not
falls under 4.1.
DCVax-L contains the following auxiliaries:
Solution: Dimethyl sulphoxide 10%
Human AB Serum 20%
RPMI-1640 tissue culture grade 70%
3. PHARMACEUTICAL FORM
Cell suspension for intradermal injection
Slightly cloudy to cloudy cell suspension
4. CLINICAL PARTICULARS
4.1 APPLICATION AREAS
DCVax-L is used for the adjuvant treatment of glioma in adults
Patient (first diagnosis or recurrence) after tumor resection and standard therapy
(Chemo- and / or radiotherapy).
4.2 RECOMMENDED DOSING, TYPE AND DURATION OF THE APPLICATION
Use google
1. NAME OF THE MEDICINAL PRODUCT
DCVax®-L 1.25 x 106
living dendritic cells / cryotubes
suspension for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACCORDING TO
ACTIVE SUBSTANCES AND OTHER INGREDIENTS
2.1 QUALITATIVE DESCRIPTION
DCVax-L contains autologous, live dendritic cells that are associated with tumor lysate antigen
of the patient were incubated (so-called antigen-presenting dendritic cells).
2.2 QUANTITATIVE DESCRIPTION
DCVax-L contains autologous, antigen-presenting dendritic cells.
One cryotube contains 250 µl of cell suspension ≥ 1.25 x 106
autologous, living
Antigen-presenting dendritic cells.
I understand - Feb or March means better numbers
I don't post more then 1 or twice every once in a while but
the emotions are gearing up tonight.
Not to be negative but I just skim over posts with numbers today -
Just been here to long
I don't have to be convinced
I remember the first time I decided to purchase this stock.
I read at least 200 posts here and watched every video that I could find
Crazy
tryn2 - You must be watching as much I as do during the day.
I can't believe how many shares I have accumulated.
Some here thinks its not the correct place to list total numbers, so I won't ---
But I took the position of buying every payday and it added up over the years
I think my largest purchase was 50K shares at .20
Lets get this project moving ----- Everyone that talks about cancer in my area turns my head. I listen to see if I can insert the info that I learned here.
The crazy thing is that it happens so much
To Better Days
Know-fear
It was Noted that Bigger really didn't say much if anything after that visit -- very strange with someone that posts on Twitter everyday .
And seems to enjoy posting. '
Just a quick picture outside the building
Makes you wonder -- Silents and not from the company this time
I hope you win !!!
One of these days this message board is going to go Crazy
We won't be able to read all the posts, anyone mentioning the price will be out of date because of all the movement
I'm not saying that its been a very long wait and the lack of news has been difficult. At the end it will pay off -
To many bread-crumbs
Just would like to point out that this person started there DCVAX after their third Surgery. Therefore the re-occurrence started without DCVAX.
66 yr old rGBM patient just celebrated 52 mths since dx and 37 mths since his 3rd surgery that removed 70% of tumor (2nd recurrence). He is only using DCVax-L as treatment. It either works or we're the luckiest people alive. No side effects.
More
Replying to @Elainzo @justinkeister5 @biggercapital
Yes, he was dx in July 2014, 2nd surgery June 2015 (full resection), 3rd surgery Oct 2015 (70% resection of approx 4cm tumour). He started DCVax after 3rd & has been stable. He continues to improve in cognitive function and mobility.
I'm going to Leak ! --- So nice for this patient
On a serious side :
Its another bread crumb
Do I know more than Mr. Bigger ---- NO
Do I have more years of Investing than Mr. Bigger ---- NO
Do I know more people than Mr Bigger ---- NO
I'm I a better investor than Mr. Bigger ---- NO
Is that a bread Crumb ---- YES
DON'T MAKE ME LEAK
LOL OK - but a date was requested not a range
Could I change mine all of 2019
Just a little fun ! -- While we wait -- wait -- wait
So much for anyone winning the cruise by selecting the Phase 3 announcement date. LOL
There should of been an entry fee ! ---- The person that started it could of cleaned up --- LOL
Looks like Mr. Bigger is our Angel
Tweeter Account
Michael Bigger
?
@biggercapital
25m25 minutes ago
More
Participated.
Northwest Bio secures $5M in bridge funding https://seekingalpha.com/news/3408908-northwest-bio-secures-5m-bridge-funding?source=tweet … $NWBO #district2capital #biggercapital
Notes With 50% Warrants Exercisable at $0.35 Per Share
BETHESDA, Md., Nov. 13, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it completed an aggregate financing of $5 million from long term angel investors.
The notes have a one-year maturity, subject to the Company's right to prepay the loan at any time by paying the principal plus the interest due until maturity, and subject to the holders' rights to require prepayment of the principal and accrued interest after 4 months. The Notes carry an interest rate of 10%, with OID of 5%. The notes carry 50% warrant coverage, with a warrant exercise price of $0.35 per share and an exercise period of 2 years.
The Company also agreed with the Company's CEO, Linda Powers, on further extensions of the Demand Notes relating to the $5.4 million of funding which Ms. Powers provided to the Company in February, March and April of 2018 as a short-term bridge. The further extensions will extend the notes to a maturity of one year from the funding dates. In consideration of this continuing forbearance, the Company will issue 50% warrants with the same exercise price and exercise period as in the angel investors' notes.
The note proceeds are being used for ongoing company programs and operations.
\
And let the conversations begin !
Hi Chris -- Don't hold back posting here -- We almost are related, my son is a Pharmacist. PharmD - Hospital LOL
Chris - posted this new article on his Twitter account today
Enjoy
https://seekingalpha.com/instablog/49123839-bwells18/5234734-recently-released-interim-data-northwest-biotherapeutics-dcvax-l-hints-upcoming-blockbuster
Makes perfect sense to take advantage of Dr LL next week, Let her present and tell the public how great the result are. -- Harder for the big F to write a negative article about her then management.
But
If Not next week - No way during the week of Thanksgiving week - Not enough days to run. With the Market closed - out of sight - Out of mind -- and Lose momentum
Possible the last week of Nov but people slowing coming back from the holiday maybe extended time off.
Unfortunately that brings us to Dec - I don't know about that between this date and that date --- people can get pretty wide with their dates LOL Kidding. I like Thursdays but I'll go for
Dec 4th
Hoping For Next Week --- Dr LL Deserves The Glory
Don't Make Me Leak
I know a company that sets up the booths for companies.
They also store the displays for the companies.
Its the same booth / display that goes to every conference
therefore the same space
At one time he brought me into McCormick Place during the setup so I can see what was going on with a companies booth.
Different Company and nothing was seen LOl
Also the communication guy from that company would bring in stock holders into the conference by giving them a fake badge
LOl
Agree --- Good Point -- yes they don't have to bring the site down
Trying to come up with a reason to bring it down for updates --- Can't
Unless its a rookie working the site LOLOLOL
or just a complete overhaul --- still I Agree with you
Anyone remember the last time it was brought back up.
The number of days would be interesting, Websites are purchased Monthly.
Does this turn off fall directly on the month?
Another subject: maybe that secret meeting in Canada that was found by this message board had something to do with this combo of companies recently located.
I really don't understand the Synergy between the companies.
What does each one bring to the game,
If they are working together somehow---- Big If
I was on the Website Just After the close today
For what its worth
Trades going to 5 decimal positions to get between the bid and ask LOl
Whats next 6 or 7 decimals
Last post I stated what the vol, for normal stocks yes but we are a little abnormal LOL
Hopefully we will be normal very soon .
If nothing this month I will rethink and maybe sell 10% or a little more each few weeks.
Don't like that but so many opportunities going by
Nothing will come out during the Holidays
Don't Make Me Leak
Better than 50 / 50
How much better ?
Watch the volume leading up to next week.
As the volume goes up so does the odds
Other applications? -- Terrific
So what is it worth now????
Not looking for an answer just sticking to a few posters I guess
There are so many breadcrumbs
Yes - here are all the docs associated with this paper
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Joseph Antonios Richard Everson Horacio Soto Sara Khattab Jacob Bethel Matthew Sun Aaron Mochizuki Alexander Lee Sylvia Odesa Emma Billingslea-Yoon Diana Moughon Anthony Wang Tim Cloughesy Robert Prins Linda Liau
Neuro-Oncology, Volume 20, Issue suppl_6, 5 November 2018, Pages vi10, https://doi.org/10.1093/neuonc/noy148.034
Published: 05 November 2018
Yes !
Maybe this message board can coordinate something
Especially for the kids
Well Tilt - I'm worried, every time I purchase the price goes down.
I haven't picked up shares for a while but broke that string of weeks today.
Happy to purchased under .20 today
Lets see where we go from here
Its not good when you own more shares then the total vol
Don't make me Leak !
Yes - I do and it shows nothing .
It states -- No quote data available in this book, Please select another.
Don't know if this is different from previous days .
No excitement here yet --- I've been trained by this stock
tryn --- Me too
I understand --- I lost my head for a minute
Since I stopped my purchasing - the disposal income is starting to pile up
Having to hold myself back to purchase more shares LOLOLOL
I used to purchase every payday --- As a terrific man used to say
Holy Cow
All longs should go silent
It will drive a few people here crazy
Although new investors would not understand as they visit the site.
Just looking to jab at a few people here
Why not ----- I think we looked at the numbers right side up and up side down.
Missing NICE Approval
Looks OK for speculation sake but I can't agree on how much time for approval.
At most a FDA panel review which takes 3 months once its announced.
3 months to take place and another 1 or 2 months till recommendation
Recommendation is basically approval - yea FDA needs to come back with final final final stuff.
All this while price does continue to move up AND DCVAX Direct continues its Phase 3 testing.
My African Grey keeps saying
Buy more DCVAX -- Buy more DCVAX
Its must be easier for him to say DCVAX then the company name
Also
I know my wife didn't teach him to say that !!!!!!
This is big !
Doc - I have often thought of no SOC patients and how they would do. I always thought that staying off of Chemo would be a good thing.
Even for the fact that patients can be treated quicker with DCVAX.
But then I think that I read somewhere that DCVAX needed the Chemo in order for it to work better (To attack the tumor) ----- I'm not sure about that now
Would be nice if we can see some follow through on Tuesday - maybe hit .25 and fall back to somewhere a 10% gain for the day. Its all about percentages until news.
I was fully invested and haven't purchased any shares for a few months but then there was today. I picked up a few crumbs just to round off my total number of shares.
Easier to play games with on the calculator --- wink wink
Very good point -- we keep looking at the stats over and over again and we might be missing something right in front of our Face.
jdheart - With this I agree with you
I even go anything beyond 5 years
If the tumor reoccurs - just go through the DCVAX again
Especially 10 years which is a very very long time.
50 year today reoccurs at 60 years old -- Goes through DCVAX more time and they are somewhere between 65 and 70 --- that may be their normal life span for their genetics
Another point I like to make -- Which big Pharma is going to be left outside looking in? I just can't understand the CEO's of large Pharma.
Are they just to Closed minded to make a simple decision like this.
The Outsiders are going to lose business and Quickly
I watch the Cancer Centers commercials on TV and think there is a business that might go out of business once DCVAX is approved unless they adjust QUICKLY.
All this now without any future improvements to DCVAX.
A once in a life time Investment
No Brain er
Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal
Bristol-Myers Squibb Co. BMY, +0.02% said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains," said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. "We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer." Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 SPX, +1.42% has gained 2.1%.
Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market
Interesting .... Step up to the plate - Pay what its worth -
All solid Tumors
This will send Merck on its Back
Roche Holding AG is starting to look more like a niche player in the hottest new field in oncology, as lung-cancer study results unveiled on Monday failed to meet the benchmark set by U.S. rival Merck & Co. It’s still unclear whether and how much Roche’s drug Tecentriq can extend the lives of patients with the most common type of lung cancer when added to chemotherapy, the Basel, Switzerland-based company said in a patient trial presented Monday at the World Conference on Lung Cancer in Toronto. The results mean Roche will need to concentrate for now on less common -- and less lucrative -- types of tumors. ...
https://www.yahoo.com/lifestyle/m/ce872370-4ff3-3660-b96d-46b946cfc64c/roche-left-seeking-a-niche-as.html
GD - Your favorite CEO just did a tap dance around the production questions during his interview 3 minutes ago on CNBC.
NOW - NorthWest would have a different story - All signs are production is ready, has been expanded and within multiple countries.
No Tap dance here !